Despite the broad CLDN18.2 eligibility criteria used in this trial (≥40% of tumor cells expressing Claudin 18.2), additional studies have demonstrated similar rates of HER2 positivity among CLDN18.2 tumors [54,56]. Here, ERBB2 is linked to neoplasm.